Covidien Receives Japanese Regulatory Approval for Reinforced Stapling Reload Technology

  Covidien Receives Japanese Regulatory Approval for Reinforced Stapling
  Reload Technology

Business Wire

DUBLIN, Ireland -- January 27, 2014

Covidien plc (NYSE: COV) today announced that its Japanese subsidiary,
Covidien Japan Inc., has received Shonin approval from the Japanese Ministry
of Health, Labor and Welfare for its Endo GIA™ Reinforced Reload with
Tri-Staple™ technology. This approval extends Covidien’s industry-leading
portfolio of advanced surgical staplers and represents a return by the company
to the Japanese stapling buttress market.

The newly approved Endo GIA Reinforced Reload will enable surgeons to deliver
an advanced polymer felt material to provide additional support to fragile
tissues when deploying Covidien’s Tri-Staple™ surgical stapling technology.
The buttressing material itself is a version of NEOVEIL® felt, developed by
GUNZE Ltd., which has been validated clinically in the Japanese market for
more than 20 years.

“This approval enables Covidien to offer an innovative technology that
supports the company’s vision of improving patient outcomes and expanding
global access to care,” said Ryo Noda, president, Covidien Japan. “Integrating
tissue stapling with buttress provides surgeons with both greater
functionality and efficiency.”

Covidien expects to begin offering Endo GIA Reinforced Reload with Tri-Staple
Technology in the Japanese market in the coming months.

About Covidien

Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers value
through clinical leadership and excellence. Covidien develops, manufactures
and sells a diverse range of industry-leading medical device and supply
products. With 2013 revenue of $10.2 billion, Covidien has more than 38,000
employees worldwide in more than 70 countries, and its products are sold in
over 150 countries. Please visit www.covidien.com to learn more about our
business.

FORWARD-LOOKING STATEMENTS

Any statements contained in this communication that do not describe historical
facts may constitute forward-looking statements as that term is defined in the
Private Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on our management's current beliefs and
expectations, but are subject to a number of risks, uncertainties and changes
in circumstances, which may cause actual results or Company actions to differ
materially from what is expressed or implied by these statements. The factors
that could cause actual future results to differ materially from current
expectations include, but are not limited to, our ability to effectively
introduce and market new products, keep pace with advances in technology and
compete effectively, implementation of healthcare reform in the United States
and globally, cost-containment efforts of customers, purchasing groups,
third-party payors and governmental organizations, rising commodity costs,
risk of cyber-attacks, intellectual property rights disputes, complex and
costly regulation, including healthcare fraud and abuse regulations and the
Foreign Corrupt Practices Act, recalls or safety alerts and negative publicity
relating to Covidien or its products, product liability losses and other
litigation liability, manufacturing or supply chain problems or disruptions,
divestitures of some of our businesses or product lines, our ability to
execute strategic acquisitions of, investments in or alliances with other
companies and businesses, risks associated with doing business outside of the
United States, foreign currency exchange rates, environmental liabilities and
tax legislation and potential tax liabilities. These and other factors are
identified and described in more detail in our Annual Report on Form 10-K for
the fiscal year ended September 27, 2013, and in subsequent filings with the
SEC. We disclaim any obligation to update these forward-looking statements
other than as required by law.

Contact:

Covidien
Peter Lucht, 508-452-4168
Vice President, External Communications
peter.lucht@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President, Investor Relations
cole.lannum@covidien.com
or
John Jordan, 508-452-4891
Manager, Communications
John.jordan@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director, Investor Relations
todd.carpenter@covidien.com
 
Press spacebar to pause and continue. Press esc to stop.